P0DTC2 (SPIKE_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Spike glycoprotein UniProtKBInterProInteractive Modelling
1273 aa; Sequence (Fasta) ;
2 identical sequences: Severe acute respiratory syndrome coronavirus 2: A0A679G9E9, A0A6G7K2L4
It is possible new templates exist for this target since these models were created.
Available Structures
1316 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| SARS-CoV-2 Omicron variant spike protein with two XGv347 binding to two open state RBDs |
Heteromer | 15×NAG; 5×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike protein with three XGv347 Fabs binding to three closed state RBDs |
Heteromer | 16×NAG; 5×NAG; 31×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv289 |
Heteromer | 15×NAG; 5×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike protein in complex with two XGv347 binding to one close state RBD … |
Heteromer | 15×NAG; 5×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv282 |
Heteromer | 16×NAG; 5×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265 |
Heteromer | 14×NAG; 5×NAG; 26×NAG; | ||||
| Assess | ||||||
| Neutral Omicron Spike Trimer in complex with ACE2 |
Heteromer Q9BYF1; | 16×NAG; 5×NAG; 34×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike protein (2-up RBD) bound to neutralizing nanobodies P86 |
Heteromer | 17×NAG; 3×NAG; 6×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike in complex with Fab XGv264 |
Heteromer | 36×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike in complex with Fab XGv051 |
Heteromer | 15×NAG; 5×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike in complex with Fab XGv286 |
Heteromer | 12×NAG; 6×NAG; 28×NAG; | ||||
| Assess | ||||||
| Three RBD-down state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab… |
Heteromer | 6×NAG; 24×NAG; 6×NAG; 21×NAG; | ||||
| Assess | ||||||
| One RBD-up state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab fra… |
Heteromer | 16×NAG; 12×NAG; 6×NAG; 23×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C3 state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C1 state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| SARS-CoV-2 Beta spike in complex with two S5D2 Fabs |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Beta spike in complex with three S3H3 Fabs |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Beta spike in complex with three S5D2 Fabs |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2A state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2B state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| SARS-CoV-2 Beta spike in complex with one S5D2 Fab |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Beta spike in complex with two S3H3 Fabs |
Heteromer | |||||
| Assess | ||||||
| Camel nanobodies 7A3 and 8A2 broadly neutralize SARS-CoV-2 variants |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets t… |
Heteromer | 13×NAG; 1×NAG; 27×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets t… |
Heteromer | 4×NAG; 15×NAG; 3×NAG; 27×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with antibodies B1-182.1 and A19-61.1 |
Heteromer | 9×NAG; 25×NAG; | ||||
| Assess | ||||||
| SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21F2 |
Heteromer | 5×NAG; 22×NAG; | ||||
| Assess | ||||||
| Beta-06 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 12×NAG; 28×NAG; | ||||
| Assess | ||||||
| Beta-43 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 12×NAG; 29×NAG; | ||||
| Assess | ||||||
| COVOX-222 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 12×NAG; 28×NAG; | ||||
| Assess | ||||||
| OMI-2 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE |
Heteromer | 12×NAG; 28×NAG; | ||||
| Assess | ||||||
| OMI-42 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8 |
Heteromer | 4×NAG; 7×NAG; 1×NAG; 7×NAG; 1×NAG; 1×NAG; 1×NAG; 32×NAG; 1×AH2; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1) |
Heteromer | 18×NAG; 24×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron closed state spike protein in complex with S3H3 Fab |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2) |
Heteromer | 18×NAG; 24×NAG; | ||||
| Assess | ||||||
| Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed st… |
Heteromer | 14×NAG; 16×NAG; | ||||
| Assess | ||||||
| P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein |
Heteromer | 15×NAG; 16×NAG; | ||||
| Assess | ||||||
| S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab. |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail |
Heteromer | 15×NAG; 16×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… |
Heteromer Q9BYF1; | 18×NAG; 42×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab. |
Heteromer | |||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159 |
Heteromer | 15×NAG; 24×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 |
Heteromer | 18×NAG; 24×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S-ACE2 complex |
Heteromer Q9BYF1; | 18×NAG; 36×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Delta S-8D3 |
Heteromer | |||||
| Assess | ||||||
| S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of Omicron S-ACE2, C2 state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… |
Heteromer Q9BYF1; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C2b |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state |
Heteromer | 27×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycopro… |
Heteromer | 3×NAG; 18×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail |
Heteromer | 15×NAG; 16×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail |
Heteromer | 14×NAG; | ||||
| Assess | ||||||
| S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab. |
Heteromer | |||||
| Assess | ||||||
| S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab. |
Heteromer | |||||
| Assess | ||||||
| S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with… |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C3 |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159 |
Heteromer | 15×NAG; 24×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in complex with ACE2, state C2a |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer Q9BYF1; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C2a |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 16×NAG; 2×NAG; 36×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C3 state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| XG005-bound SARS-CoV-2 S |
Heteromer | 45×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the 87G7 antibody Fab fragment |
Heteromer | 12×NAG; 27×NAG; | ||||
| Assess | ||||||
| S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab. |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein with ACE2, C1 state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike |
Heteromer | 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 17×NAG; 3×NAG; 34×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… |
Heteromer Q9BYF1; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spi… |
Heteromer | 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer Q9BYF1; | 18×NAG; 32×NAG; | ||||
| Assess | ||||||
| S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Delta S-ACE2-C1 |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C2 state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 24×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron open state spike protein in complex with S3H3 Fab |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… |
Heteromer Q9BYF1; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 18×NAG; 34×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… |
Heteromer Q9BYF1; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| The state 1 complex structure of Omicron spike with Bn03 (1-up RBD, 3 nanobodies) |
Heteromer | 40×NAG; | ||||
| Assess | ||||||
| The state 3 complex structure of Omicron spike with Bn03 (2-up RBD, 5 nanobodies) |
Heteromer | 28×NAG; | ||||
| Assess | ||||||
| The state 2 complex structure of Omicron spike with Bn03 (2-up RBD, 4 nanobodies) |
Heteromer | 36×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of NTD-directed neutralizing antibody LP5 Fab in complex with SARS-CoV-2 S2P spike |
Heteromer | 3×NAG; 3×NAG; 1×NAG; 28×NAG; | ||||
| Assess | ||||||
| Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… |
Heteromer | 14×NAG; 10×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer Q9BYF1; | 14×NAG; 20×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 14×NAG; 10×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer Q9BYF1; | 14×NAG; 12×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 dimer trimer ) |
Heteromer | 90×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with IgG 553-60 (1-up trimer) |
Heteromer | 39×NAG; | ||||
| Assess | ||||||
| Omicron Spike bitrimer with 6m6 antibody |
Heteromer | 49×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with IgG 553-60 (2-up trimer) |
Heteromer | 38×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 trimer) |
Heteromer | 45×NAG; | ||||
| Assess | ||||||
| CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinemen… |
Heteromer | 10×NAG; 20×NAG; | ||||
| Assess | ||||||
| CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinement) |
Heteromer | 5×NAG; 1×NAG; 29×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 18×NAG; 36×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 18×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… |
Heteromer Q9BYF1; | 23×NAG; 24×NAG; 2×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 D614G spike protein in complex with VH ab6 |
Heteromer | 18×NAG; 21×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 18×NAG; 42×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 18×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6 |
Heteromer | 18×NAG; 23×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutat… |
Heteromer Q9BYF1; | 15×NAG; 33×NAG; 3×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… |
Heteromer Q9BYF1; | 22×NAG; 23×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with S309 fab |
Heteromer | 19×NAG; 25×NAG; | ||||
| Assess | ||||||
| Furin Site deletion of SARS-CoV-2 spike |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of RBD-directed neutralizing antibody P2B4 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 44×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 2 YB9-258 Fabs (2 RBD up) |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (1 RBD up) |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (2 RBD up) |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (3 RBD down) |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 1 YB9-258 Fab (1 RBD up) |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8 |
Heteromer | 18×NAG; 21×NAG; | ||||
| Assess | ||||||
| Nanobody C5 bound to Spike |
Heteromer | 15×NAG; 36×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S trimer with four-antibody cocktail complex |
Heteromer | 12×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S trimer with three-antibody cocktail complex |
Heteromer | 15×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in C3 state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in C2b state |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| VAS5 Spike (1 RBD up) |
Heteromer | 13×NAG; 31×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment |
Heteromer | 12×NAG; 3×NAG; 36×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 37×NAG; 13×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S-6P in complex with 9 Fabs |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer Q9BYF1; | 30×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron Variant SPIKE trimer complexed with ACE2 |
Heteromer Q9BYF1; | 12×NAG; 21×NAG; 1×CL; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1) |
Heteromer | 12×NAG; 39×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 43×NAG; 14×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up confor… |
Heteromer | 8×NAG; 45×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike glycoprotein:Fab 5A6 complex I |
Heteromer | 23×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound |
Heteromer Q9BYF1; | 23×NAG; 1×ZN; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014 |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer Q9BYF1; | 29×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4 |
Heteromer | 4×NAG; 33×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) |
Heteromer | 9×NAG; 45×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with nanobodies E |
Heteromer | 51×NAG; | ||||
| Assess | ||||||
| Beta-26 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 13×NAG; 31×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 38×NAG; 16×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… |
Heteromer | 20×NAG; 2×NAG; 21×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike glycoprotein:Fab 3D11 complex |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer Q9BYF1; | 30×NAG; 1×NAG; 19×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Kappa variant spike protein in complex wth ACE2, state C1 |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351) in complex with Angiotensin-converting enz… |
Heteromer Q9BYF1; | 31×NAG; 17×NAG; | ||||
| Assess | ||||||
| CryoEm structure of SARS-CoV-2 spike protein (S-6P, 1-up) in complex with sybodies (Sb45) |
Heteromer | 19×NAG; 35×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with 4A8 |
Heteromer | 6×NAG; 23×NAG; 25×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 37×NAG; 15×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| SARS-CoV-2 Spike (dimers) in complex with six Fu2 nanobodies |
Heteromer | 2×NAG; 46×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with non-neutralizing NTD-directed CV3-13 Fab isol… |
Heteromer | 3×NAG; 36×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 31×NAG; 13×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction |
Heteromer Q9BYF1; | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… |
Heteromer | 3×NAG; 12×NAG; 18×NAG; | ||||
| Assess | ||||||
| Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab |
Heteromer | 25×NAG; 2×BLA; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-spike bound to two neutralising nanobodies |
Heteromer | 1×NAG; 42×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex with 2G1 |
Heteromer | 24×NAG; 30×NAG; 3×EIC; | ||||
| Assess | ||||||
| CryoEM structure of SARS-CoV-2 spike protein (S-6P, 2-up) in complex with sybodies (Sb45) |
Heteromer | 17×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with PVI.V6-14 Fab |
Heteromer | 15×NAG; 6×NAG; 6×NAG; 3×NAG; 18×NAG; | ||||
| Assess | ||||||
| J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 1) |
Heteromer | 9×NAG; 15×NAG; | ||||
| Assess | ||||||
| J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 2) |
Heteromer | 12×NAG; 21×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 18×NAG; 30×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 18×NAG; 30×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 15×NAG; 24×NAG; | ||||
| Assess | ||||||
| The SARS-CoV-2 spike in complex with the 1.29 neutralizing nanobody |
Heteromer | 5×NAG; 33×NAG; | ||||
| Assess | ||||||
| The SARS-CoV-2 spike in complex with the 2.15 neutralizing nanobody |
Heteromer | 5×NAG; 33×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-23 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57 |
Heteromer | 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-22 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-45 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-65 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67 |
Heteromer | 14×NAG; 4×NAG; 2×NAG; 32×NAG; | ||||
| Assess | ||||||
| CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of N12-9 |
Heteromer | 10×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs |
Heteromer | 6×NAG; 24×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2 |
Heteromer Q9BYF1; | 6×NAG; 36×NAG; 3×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab |
Heteromer | 6×NAG; 24×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs |
Heteromer | 6×NAG; 24×NAG; | ||||
| Assess | ||||||
| The SARS-CoV-2 spike in complex with the 1.10 neutralizing nanobody |
Heteromer | 5×NAG; 33×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… |
Heteromer | 16×NAG; 20×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-57 (three down conformation) |
Heteromer | 28×NAG; 25×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin |
Heteromer | 3×NAG; 9×NAG; 6×NAG; 18×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 wildtype spike trimer (6P) in complex with 3 YB9-258 Fabs and 3 R1-32 Fabs (3 RBD up) |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 |
Heteromer Q8R0I0; | 22×NAG; 23×NAG; 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 S B.1.1.529 Omicron variant + S309 + S2L20 Global Refinement |
Heteromer | 1×NAG; 50×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement |
Heteromer | 51×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement |
Heteromer | 3×NAG; 45×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibodies A19-46.1 and B1-182.1 |
Heteromer | 13×NAG; 15×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C15… |
Heteromer | 12×NAG; 35×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S/S2M11/S2M28 Global Refinement |
Heteromer | 3×NAG; 6×NAG; 45×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 sp… |
Heteromer | 6×NAG; 48×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S/S2M11/S2X333 Global Refinement |
Heteromer | 3×NAG; 6×NAG; 45×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibody A19-46.1 |
Heteromer | 14×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S B.1.617.1 kappa variant + S2X303 Global Refinement |
Heteromer | 3×NAG; 51×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fa… |
Heteromer | 1×NAG; 48×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of huma… |
Heteromer | 29×NAG; 25×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 Spike trimer with three RBDs up in complex with the Fab fragment of hum… |
Heteromer | 33×NAG; 21×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S/S2M11/S2L28 Global Refinement |
Heteromer | 3×NAG; 9×NAG; 3×NAG; 39×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2 variant spike protein in complex with Fab BD55-5840 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 S Omicron Spike B.1.1.529 - 3-P2G3 and 1-P5C3 Fabs (Global) |
Heteromer | 14×NAG; 1×NAG; 2×NAG; 26×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with two RBDs down in complex with the Fab … |
Heteromer | 27×NAG; 19×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with one RBD down in complex with the Fab f… |
Heteromer | 20×NAG; 23×NAG; | ||||
| Assess | ||||||
| CryoEM structure of neutralizing nanobody Nb12 in complex with SARS-CoV2 spike |
Heteromer | 5×NAG; 13×NAG; 22×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations… |
Heteromer | 10×NAG; 27×NAG; | ||||
| Assess | ||||||
| cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound |
Heteromer | 21×NAG; 6×NAG; 18×NAG; | ||||
| Assess | ||||||
| Beta-50 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 1×NAG; 14×NAG; 2×NAG; 25×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548 |
Heteromer | 5×NAG; 1×NAG; 1×NAG; 1×NAG; 26×NAG; | ||||
| Assess | ||||||
| Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment |
Heteromer | 18×NAG; 3×NAG; 30×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051 |
Heteromer | 4×NAG; 27×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 1×NAG; 32×NAG; | ||||
| Assess | ||||||
| Beta049 fab in complex with SARS-CoV2 beta-Spike glycoprotein, The Beta mAb response underscores th… |
Heteromer | 2×NAG; 14×NAG; 1×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with Fab S2M11 |
Heteromer | 18×NAG; 3×NAG; 30×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-3 |
Heteromer | 3×NAG; 45×NAG; | ||||
| Assess | ||||||
| cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound |
Heteromer | 7×NAG; 2×NAG; 25×NAG; | ||||
| Assess | ||||||
| Omicron spike trimer with 6m6 antibody |
Heteromer | 24×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of double ACE2-bound SARS-CoV-2 trimer Spike at pH 7.4 |
Heteromer Q9BYF1; | 4×NAG; 53×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with sybodyb#15 in a 1up/1up-out/1down conformation. |
Heteromer | 4×NAG; 8×NAG; 3×NAG; 1×NAG; 19×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of triple ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer Q9BYF1; | 8×NAG; 55×NAG; | ||||
| Assess | ||||||
| Cryo-EM Structure of Double ACE2-Bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer Q9BYF1; | 4×NAG; 48×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with sybody#68 in a 2up/1flexible conformation |
Heteromer | 10×NAG; 4×NAG; 1×NAG; 1×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation |
Heteromer | 10×NAG; 4×NAG; 1×NAG; 1×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with LCB1 (2RBDs open) |
Heteromer | 13×NAG; 33×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer Q9BYF1; | 6×NAG; 56×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike … |
Heteromer | 16×NAG; 9×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 1up/1up-out/1down conformation |
Heteromer | 11×NAG; 4×NAG; 1×NAG; 19×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-"up", asymmetric |
Heteromer | 2×NAG; 1×NAG; 7×NAG; | ||||
| Assess | ||||||
| 3D model of the 3-RBD up single trimeric spike protein of SARS-CoV2 in the presence of synthetic pe… |
Heteromer | 39×NAG; | ||||
| Assess | ||||||
| CryoEM structure of neutralizing nanobody Nb30 in complex with SARS-CoV2 spike |
Heteromer | 11×NAG; 4×NAG; 1×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-"up"-1-"down" conformation |
Heteromer | 12×NAG; 3×NAG; 16×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S (Spike Glycoprotein) D614G with Three (3) RBDs Up, Bound to Antibody 2-7 scFv, composi… |
Heteromer | 3×NAG; 45×NAG; | ||||
| Assess | ||||||
| The state 5 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 18×NAG; | ||||
| Assess | ||||||
| The state 4 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 23×NAG; | ||||
| Assess | ||||||
| The state 2 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 23×NAG; | ||||
| Assess | ||||||
| The state 3 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 21×NAG; | ||||
| Assess | ||||||
| The state 1 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 28×NAG; | ||||
| Assess | ||||||
| The state 6 of Omicron Spike with bispecific antibody FD01 |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 5.5 |
Heteromer Q9BYF1; | 6×NAG; 44×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab. |
Heteromer | 15×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab |
Heteromer | 15×NAG; 30×NAG; | ||||
| Assess | ||||||
| CryoEM structure of SARS-CoV-2 Spike in complex with Nb17 |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer Q9BYF1; | 5×NAG; 46×NAG; | ||||
| Assess | ||||||
| Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27 |
Heteromer | 15×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab |
Heteromer | 15×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 |
Heteromer | 12×NAG; 50×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state1) |
Heteromer Q9BYF1; | 9×NAG; 1×ZN; 1×CL; 49×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state2) |
Heteromer Q9BYF1; | 9×NAG; 53×NAG; 2×ZN; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state1) |
Heteromer | 9×NAG; 2×NAG; 45×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state2) |
Heteromer | 9×NAG; 3×NAG; 45×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state3) |
Heteromer | 2×NAG; 45×NAG; | ||||
| Assess | ||||||
| Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 spike in prefusion state |
Heteromer | 16×NAG; 4×NAG; 7×NAG; 18×NAG; 2×MAN; 3×DMS; | ||||
| Assess | ||||||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 2Up1Down conformation |
Heteromer | 20×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three F61 Fab |
Heteromer | 24×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-34 |
Heteromer | 42×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-28 |
Heteromer | 39×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, HSW-1 |
Heteromer | 2×NAG; 34×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-31 |
Heteromer | 3×NAG; 39×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab |
Heteromer | 11×NAG; 27×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab |
Heteromer | 11×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6 |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6 |
Heteromer | 18×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation) |
Heteromer | 15×NAG; 33×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 3×NAG; 1×NAG; 1×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12 |
Heteromer | 8×NAG; 2×NAG; 2×NAG; 2×NAG; 25×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab |
Heteromer | 15×NAG; 1×NAG; 2×NAG; 30×NAG; | ||||
| Assess | ||||||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the M1 conformation, D4 |
Heteromer | 12×NAG; 22×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 out RBD, state3) |
Heteromer | 27×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 1×NAG; 2×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 10×NAG; 21×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab |
Heteromer | 10×NAG; 1×NAG; 27×NAG; | ||||
| Assess | ||||||
| Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab |
Heteromer | 12×NAG; 35×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab |
Heteromer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(3 up RBDs, state2) |
Heteromer | 27×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 15×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with two ACE2 Bound |
Heteromer Q9BYF1; | 20×NAG; 40×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 15×NAG; 30×NAG; | ||||
| Assess | ||||||
| Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2 |
Heteromer | |||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab |
Heteromer | 10×NAG; 1×NAG; 27×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab … |
Heteromer | 10×NAG; 3×NAG; 1×NAG; 1×NAG; 1×NAG; 1×MAN; 28×NAG; 3×FUC; 2×MAN; | ||||
| Assess | ||||||
| SARS CoV2 Spike ectodomain with engineered trimerized VH binder |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with three T6… |
Heteromer | 25×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation) |
Heteromer | 12×NAG; 21×NAG; 3×NAG; 3×NAG; 3×NAG; 3×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7) in complex with Angiotensin-converting enzym… |
Heteromer Q9BYF1; | 29×NAG; 26×NAG; | ||||
| Assess | ||||||
| Mink Cluster 5-associated SARS-CoV-2 spike protein(S-GSAS-D614G-delFV) missing the S1 subunit and S… |
Heteromer | 1×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with three ACE2 Bound |
Heteromer Q9BYF1; | 24×NAG; 42×NAG; | ||||
| Assess | ||||||
| Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with Fab of m31A7 |
Heteromer | 2×NAG; 8×NAG; 2×NAG; 4×NAG; 3×NAG; 2×NAG; 1×NAG; 1×NAG; 1×NAG; 19×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab |
Heteromer | 14×NAG; 1×NAG; 32×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041 |
Heteromer | 11×NAG; 6×NAG; 17×NAG; | ||||
| Assess | ||||||
| Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex |
Heteromer | 20×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D r… |
Heteromer | 10×NAG; 1×NAG; 1×NAG; 1×NAG; 32×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab |
Heteromer | 15×NAG; 3×NAG; 25×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… |
Heteromer | 9×NAG; 1×NAG; 2×NAG; 1×NAG; 30×NAG; | ||||
| Assess | ||||||
| Beta-53 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 2×NAG; 11×NAG; 15×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 B.1.1.7 S-ACE2 complex |
Heteromer Q9BYF1; | 16×NAG; 27×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 down RBD, state1) |
Heteromer | 27×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… |
Heteromer | 9×NAG; 3×NAG; 3×NAG; 24×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12 |
Heteromer | 10×NAG; 1×NAG; 1×NAG; 1×NAG; 31×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 45×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike ectodomain with Fab FI3A |
Heteromer | 11×NAG; 27×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 13×NAG; 1×NAG; 1×NAG; 33×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation) |
Heteromer | 14×NAG; 21×NAG; 3×NAG; 3×NAG; 3×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab |
Heteromer | 13×NAG; 23×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Glycoprotein with one ACE2 Bound |
Heteromer Q9BYF1; | 17×NAG; 36×NAG; | ||||
| Assess | ||||||
| Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… |
Heteromer | 22×NAG; | ||||
| Assess | ||||||
| Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… |
Heteromer | 20×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab |
Heteromer | 15×NAG; 30×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with two T6 F… |
Heteromer | 25×NAG; | ||||
| Assess | ||||||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab |
Heteromer | 11×NAG; 27×NAG; | ||||
| Assess | ||||||
| Structure of human SARS-CoV-2 spike glycoprotein trimer bound by neutralizing antibody C1C-A3 Fab (… |
Heteromer | 3×NAG; 45×NAG; | ||||
| Assess | ||||||
| Beta-32 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 15×NAG; 30×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 13×NAG; 34×NAG; | ||||
| Assess | ||||||
| J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (conformation 3) |
Heteromer | 7×NAG; 16×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down- and 2 up RBDs) |
Heteromer | 2×NAG; 27×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down-, 1 up- and 1 invisible RBDs) |
Heteromer | 27×NAG; | ||||
| Assess | ||||||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H6 nanobody complex |
Heteromer | 20×NAG; 26×NAG; | ||||
| Assess | ||||||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-B5 nanobody complex |
Heteromer | 20×NAG; 26×NAG; | ||||
| Assess | ||||||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 1Up2Down conformation |
Heteromer | 20×NAG; 26×NAG; | ||||
| Assess | ||||||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11 nanobody complex |
Heteromer | 19×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-Cov2 Omicron varient S protein structure in complex with neutralizing monoclonal antibody 002-… |
Heteromer | 13×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike protein in complex with the single chain fragment scFv76 |
Heteromer | 12×NAG; 27×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three D2 Fab |
Heteromer | 32×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 Omicron BA.1 S 6P trimer in complex with the mouse antibody Fab fragmen… |
Heteromer | 3×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Delta Spike in complex with IS-9A |
Heteromer | 4×NAG; 24×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052 |
Heteromer | 14×NAG; 31×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1 |
Heteromer | 15×NAG; 33×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047 |
Heteromer | 13×NAG; 2×NAG; 24×NAG; | ||||
| Assess | ||||||
| CryoEM structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1042 |
Heteromer | 1×NAG; 12×NAG; 33×NAG; | ||||
| Assess | ||||||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-A10 nanobody complex |
Heteromer | 20×NAG; 26×NAG; | ||||
| Assess | ||||||
| H11-H4 bound to Spike |
Heteromer | 20×NAG; 26×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 28×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 23×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with LCB3 (2RBDs open) |
Heteromer | 13×NAG; 33×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (1 up RBD and 1 PD bound) |
Heteromer Q9BYF1; | 26×NAG; 30×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs |
Heteromer | 5×NAG; 31×NAG; | ||||
| Assess | ||||||
| Furin Cleaved Alpha Variant SARS-CoV-2 Spike in complex with 3 ACE2 |
Heteromer Q9BYF1; | 3×NAG; 48×NAG; 3×ZN; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P36-5D2(state2) |
Heteromer | 17×NAG; 28×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15… |
Heteromer | 27×NAG; 21×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45 |
Heteromer | 24×NAG; 24×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B |
Heteromer | 22×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30 |
Heteromer | 13×NAG; 27×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 33×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B |
Heteromer | 21×NAG; 27×NAG; | ||||
| Assess | ||||||
| Conformation 1 of S-ACE2-B0AT1 ternary complex |
Heteromer Q695T7; Q9BYF1; | 58×NAG; 64×NAG; 2×LEU; 2×ZN; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-3A1 |
Heteromer | 22×NAG; 26×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017 |
Heteromer | 6×NAG; 19×NAG; | ||||
| Assess | ||||||
| SARS-CoV 2 Spike Protein bound to LY-CoV555 |
Heteromer | 3×NAG; 16×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25 |
Heteromer | 27×NAG; 21×NAG; | ||||
| Assess | ||||||
| BD23-Fab in complex with the S ectodomain trimer |
Heteromer | 5×NAG; 1×NAG; 32×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B |
Heteromer A0A5C2G1U0; P01834; P0DP01; V9HW68; | 21×NAG; 2×NAG; 28×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 11×NAG; 26×NAG; | ||||
| Assess | ||||||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (2 up RBD and … |
Heteromer Q9BYF1; | 32×NAG; 29×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032 |
Heteromer | 4×NAG; 1×NAG; 22×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with T-ACE2 |
Heteromer Q9BYF1; | 35×NAG; 34×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron Variant S Trimer complexed with two JMB2002 Fab |
Heteromer | 2×NAG; 36×NAG; | ||||
| Assess | ||||||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (3 up RBD and … |
Heteromer Q9BYF1; | 32×NAG; 29×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron Variant S Trimer complexed with three JMB2002 Fab |
Heteromer | 2×NAG; 35×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4 |
Heteromer A0A5C2GJG2; | 7×NAG; 3×NAG; 2×NAG; 36×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (2 up RBD and 1 PD bound) |
Heteromer Q9BYF1; | 27×NAG; 28×NAG; | ||||
| Assess | ||||||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and … |
Heteromer Q9BYF1; | 27×NAG; 28×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P36-5D2 (state1) |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Omicron Variant S Trimer complexed with one JMB2002 Fab |
Heteromer | 2×NAG; 33×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B |
Heteromer A0A5C2G1U0; P01834; P0DP01; V9HW68; | 22×NAG; 3×NAG; 27×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex with GW01 |
Heteromer | 23×NAG; 25×NAG; | ||||
| Assess | ||||||
| S protein of Delta variant in complex with ZWD12 |
Heteromer | 23×NAG; 25×NAG; | ||||
| Assess | ||||||
| S protein of Delta variant in complex with ZWC6 |
Heteromer | 23×NAG; 25×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with two mouse ACE2 Bound |
Heteromer Q8R0I0; | 39×NAG; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with one mouse ACE2 Bound |
Heteromer Q8R0I0; | 34×NAG; 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two mouse ACE2 Bound |
Heteromer Q8R0I0; | 37×NAG; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three human ACE2 Bound |
Heteromer Q9BYF1; | 39×NAG; 3×CL; 3×ZN; | ||||
| Assess | ||||||
| S-ECD (Omicron) in complex with STS165 |
Heteromer | 19×NAG; 33×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two human ACE2 Bound |
Heteromer Q9BYF1; | 39×NAG; 2×CL; 2×ZN; | ||||
| Assess | ||||||
| S-ECD (Omicron) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 23×NAG; 45×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with one mouse ACE2 Bound |
Heteromer Q8R0I0; | 37×NAG; 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three JMB2002 Fab Bound |
Heteromer | 2×NAG; 35×NAG; | ||||
| Assess | ||||||
| Cryo EM structure of SARS-CoV-2 spike in complex with TAU-2212 mAbs in conformation 4 |
Heteromer | 33×NAG; | ||||
| Assess | ||||||
| overall structure of hu33 and spike |
Heteromer | 3×NAG; 10×NAG; 26×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike glycoprotein in complex with three F61 Fab and three … |
Heteromer | 31×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-6 |
Heteromer | 48×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (3U) |
Heteromer | 18×NAG; 18×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B9 |
Heteromer A0A5C2G1U0; P01825; Q6GMX6; Q8TCD0; | 19×NAG; 33×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B |
Heteromer P01594; P0DOX5; P0DP02; Q8TCD0; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (2u1d) |
Heteromer | 17×NAG; 20×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P2B-1A1 |
Heteromer A0A5C2GM57; P01825; Q5EFE5; Q8N5F4; | 23×NAG; 28×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; Q6GMX6; Q8TCD0; | 20×NAG; 31×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P2B-1A10 |
Heteromer A0A5C2GF00; P01594; P0DOX5; Q8TCD0; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-2G7 |
Heteromer A0A0C4DH41; A0A5C2G2G8; Q6IPQ0; V9HW68; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B |
Heteromer P01594; P0DOX5; P0DP02; Q8TCD0; | 20×NAG; 31×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-2G9 |
Heteromer A0A5C2GMM2; P01772; P0DOX5; Q8N5F4; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 |
Heteromer A0A5C2GCZ2; A0A5C2GF00; Q6GMX6; Q8TCD0; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 Spike in complex with IY-2A |
Heteromer | |||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with FabP5A-2G7 |
Heteromer A0A0C4DH41; A0A5C2G2G8; Q6IPQ0; V9HW68; | 20×NAG; 29×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; Q6GMX6; Q8TCD0; | 20×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike trimer in complex with XG014 Fab |
Heteromer | 24×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C17… |
Heteromer | 6×NAG; 1×NAG; 27×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Spike with P5C3 Fab |
Heteromer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 Spike trimer with two RBDs down in complex with the Fab fragment of hum… |
Heteromer | 21×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment |
Heteromer | 12×NAG; 3×NAG; 33×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement |
Heteromer | 3×NAG; 6×NAG; 39×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open) |
Heteromer | 11×NAG; 36×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of huma… |
Heteromer | 23×NAG; 28×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1) |
Heteromer | 39×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 15×NAG; 33×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment |
Heteromer | 15×NAG; 33×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 Spike trimer with all RBDs down in complex with the Fab fragment of hum… |
Heteromer | 21×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S glycoprotein in complex with S2X259 Fab |
Heteromer | 12×NAG; 30×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation) |
Heteromer | 12×NAG; 36×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the ACE2 protein decoy, CTC-445.2 (State 4) |
Heteromer | 2×NAG; 27×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with AHB2-2GS-SB175 |
Heteromer | 12×NAG; 36×NAG; | ||||
| Assess | ||||||
| P5C3 is a potent fab neutralizer |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 BA.2.75 S Trimer in complex with XG2v024 |
Heteromer | 15×NAG; 9×NAG; 24×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7 |
Heteromer | 6×NAG; 30×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15 |
Heteromer | 7×NAG; 1×NAG; 1×NAG; 31×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43 |
Heteromer | 6×NAG; 3×NAG; 31×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (two receptor-bindin… |
Heteromer | 8×NAG; 37×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Delta Spike in complex with FP-12A |
Heteromer | 7×NAG; 21×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… |
Heteromer | 12×NAG; 3×NAG; 33×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… |
Heteromer | 10×NAG; 1×NAG; 1×NAG; 35×NAG; | ||||
| Assess | ||||||
| Major cryo-EM structure of S protein trimer of SARS-CoV2 with K-874, composite map |
Heteromer | |||||
| Assess | ||||||
| Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 S Omicron Spike B.1.1.529 - RBD and NTD (Local) |
Heteromer | 1×NAG; 2×NAG; 2×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004 |
Heteromer | |||||
| Assess | ||||||
| CryoEM structure of SARS-CoV-2 spike monomer in complex with neutralising antibody P008_60 |
Heteromer | 8×NAG; 1×3Q9; | ||||
| Assess | ||||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement) |
Heteromer Q9BYF1; | 1×NAG; 7×NAG; 1×ZN; | ||||
| Assess | ||||||
| Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 |
Heteromer Q9BYF1; | 1×ZN; 7×NAG; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 S S1 doamin in complex with the mouse antibody Fab fragment, HSW-2 |
Heteromer | 4×NAG; | ||||
| Assess | ||||||
| Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement) |
Heteromer | 2×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 wildtype S1 in complex with YB9-258 Fab and R1-32 Fab |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) complex with YB9-258 Fab, focused refinement of RBD-dimer… |
Heteromer | 7×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB9-258 Fab, focused refinement of Fab re… |
Heteromer | 7×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike trimer RBD in complex with Fab NA8 |
Heteromer | 4×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 spike trimer RBD in complex with Fab NE12 |
Heteromer | 3×NAG; | ||||
| Assess | ||||||
| Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement) |
Heteromer | 2×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction) |
Heteromer | 1×NAG; 1×NAG; 2×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 NTD in complex with N9 Fab |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab (state1, local refinement of the … |
Heteromer | 2×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 spike protein in complex with nanobody C5G2 (localized refinement) |
Heteromer | 4×NAG; | ||||
| Assess | ||||||
| Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab |
Heteromer | |||||
| Assess | ||||||
| Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667 |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of a chimeric protein mimic of SARS-CoV-2 Spike HR1 in complex with HR2 |
Heteromer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 NTD in complex with C1520, local refinement |
Heteromer | 3×NAG; 4×NAG; | ||||
| Assess | ||||||
| Structure of viral peptides IPB19/N52 |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of the N-terminal domain of SARS-CoV-2 beta variant spike glycoprotein in complex… |
Heteromer | 2×NAG; 1×NAG; 2×NAG; 6×CL; 1×PEG; 3×GOL; 1×PO4; 7×NAG; 1×PG4; | ||||
| Assess | ||||||
| SARS-CoV-2 S NTD B.1.1.529 Omicron variant + S309 Local Refinement |
Heteromer | 6×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement |
Heteromer | 1×NAG; 4×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement |
Heteromer | 1×NAG; 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4-8 (focused refineme… |
Heteromer | 6×NAG; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab |
Heteromer | 2×NAG; 2×NAG; 1×NAG; 2×NAG; 1×UNX; 1×XYL; 1×SO4; | ||||
| Assess | ||||||
| SARS-CoV-2 S NTD B.1.617.1 kappa variant S2X303 Local Refinement |
Heteromer | 1×NAG; 6×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike NTD in complex with neutralizing Fab SARS2-57 (local refinement) |
Heteromer | 2×NAG; 4×NAG; | ||||
| Assess | ||||||
| Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-termina… |
Heteromer | 1×NAG; 6×NAG; 23×CA; 3×ACT; 1×PGE; | ||||
| Assess | ||||||
| an engineered 5-helix bundle derived from SARS-CoV-2 S2 in complex with HR2P |
Heteromer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 Omicron spike post-fusion bundle |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with A942S mutation |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with V1176F mutation |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with L938F mutation |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with S940F mutation |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with D936Y mutation |
Heteromer | |||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with extended HR2 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20) |
Heteromer | 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4A8 (focused refineme… |
Heteromer | 1×NAG; 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8 (focused refinem… |
Heteromer | 1×NAG; 4×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Spike in complex with PVI.V6-14 Fab |
Heteromer A0A5C2FYK4; | 2×NAG; 3×NAG; | ||||
| Assess | ||||||
| A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2 |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction) |
Heteromer | 5×NAG; | ||||
| Assess | ||||||
| Local CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of… |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (focused refinement on Fab-RBD) |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Omicron spike protein SD1 in complex with S3H3 Fab |
Heteromer | |||||
| Assess | ||||||
| SARS-CoV-2 Beta spike SD1 in complex with S3H3 Fab |
Heteromer | |||||
| Assess | ||||||
| sd1.040 Fab in complex with SARS-CoV-2 Spike 2P glycoprotein |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 1×ZN; 8×NAG; | ||||
| Assess | ||||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 1×NAG; 7×NAG; 1×ZN; | ||||
| Assess | ||||||
| Dissociated S1 domain of Mink Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 1×ZN; 6×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with S309 fab (local refinement) |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Dissociated S1 domain of Beta Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 7×NAG; 1×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of spike binding to Fab of neutralizing antibody (locally refined) |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S-NTD + Fab CM25 |
Heteromer | |||||
| Assess | ||||||
| Antibody A7V3 bound to N-terminal domain of the spike |
Heteromer | 5×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S/S2M11/S2M28 Local Refinement |
Heteromer | 1×NAG; 2×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S/S2M11/S2L28 Local Refinement |
Heteromer | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement) |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 S/S2M11/S2X333 Local Refinement |
Heteromer | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab |
Heteromer | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| Crystallographic structure of two neutralizing nanobodies in complex with SARS-CoV-2 spike receptor… |
Heteromer | 1×NAG; 1×NAG; 3×PEG; 2×GOL; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibo… |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike:5A6 Fab complex I focused refinement |
Heteromer | 4×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Spike:Fab 3D11 complex focused refinement |
Heteromer | 2×NAG; | ||||
| Assess | ||||||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing… |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement) |
Heteromer | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6 |
Heteromer | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 RBD in complex with a human single domain antibody n3113 |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immuni… |
Heteromer Q9BYF1; | 1×NAG; 8×CL; 1×SO4; 4×NA; 1×PG5; 1×ZN; 4×NAG; 1×PGE; | ||||
| Assess | ||||||
| Structure of sybody SR31 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) |
Heteromer | 1×NAG; 13×FMT; 5×GOL; 2×ACT; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… |
Heteromer Q9BYF1; | 7×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 (focused… |
Heteromer Q9BYF1; | 7×NAG; | ||||
| Assess | ||||||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv347 |
Heteromer | |||||
| Assess | ||||||
| Local refinement of SARS-CoV-2 S-Gamma variant (P.1) RBD and Angiotensin-converting enzyme 2 (ACE2)… |
Heteromer Q9BYF1; | 5×NAG; 3×NAG; | ||||
| Assess | ||||||
| Local refinement of SARS-CoV-2 S-Beta variant (B.1.351) RBD and Angiotensin-converting enzyme 2 (AC… |
Heteromer Q9BYF1; | 3×NAG; 5×NAG; | ||||
| Assess | ||||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… |
Heteromer Q9BYF1; | |||||